duocarmycins

Seco-Duocarmycin TM is an agent of DNA alkylator belonging to Duocarmycins family that inhibits DNA synthesis. It used as the cytotoxic component in antibody-drug conjugates (ADC).

Duocarmycin A, an antitumor antibiotic, is a DNA alkylator and efficiently alkylates adenine N3 at the 3′ end of AT-rich sequences in the DNA. Duocarmycin A, as a chemotherapeutic agent, results in HLC-2 cells typically apoptotic changes.

DBCO-PEG4-VC-PAB-DMEA-PNU-159682, a drug-linker conjugate for antibody-drug conjugates (ADC), comprises the ADC linker DBCO-PEG4-VC-PAB and the potent ADC cytotoxin DMEA-PNU-159682, which includes metabolites of nemorubicin (MMDX) from liver microsomes and the ADC cytotoxin PNU-159682[1].

Fmoc-Val-Cit-PAB-Duocarmycin TM is a drug-linker conjugate intended for antibody-drug conjugation (ADC), employing the antitumor antibiotic Duocarmycin TM and connected via the linker Fmoc-Val-Cit-PAB.

Mal-PEG4-VC-PAB-DMEA-Seco-Duocarmycin SA is an antibody-drug conjugate linker, integrating the antitumor antibiotic Duocarmycin SA via the Mal-PEG4-VC-PAB-DMEA-Seco linker, aimed at targeted cancer therapy.

MC-Val-Cit-PAB-duocarmycin is an antibody-drug conjugate (ADC) linker that combines duocarmycin, a potent DNA minor groove-binding alkylating agent, with an antitumor drug through the MC-Val-Cit-PAB linker, exhibiting significant antitumor activity.

Vc-seco-DUBA (Duocarmazine) is a linker-payload conjugate designed for the synthesis of Antibody-Drug Conjugates (ADCs). It consists of the potent DNA alkylating payload DUBA (a duocarmycin analog) connected via the Vc-seco linker. This conjugate is engineered to enable the targeted delivery of highly cytotoxic DNA-alkylating agents specifically to tumor cells through antibody guidance. DUBA exerts its effect by binding to the minor groove of DNA and causing alkylation, which leads to DNA damage and subsequent apoptosis, demonstrating potent antitumor efficacy.

Duocarmycin SA is an extremely potent cytotoxic agent and antitumor antibiotic that induces sequence-selective alkylation of duplex DNA, with an IC50 of 10 pM. It demonstrates synergistic cytotoxicity against glioblastoma multiforme (GBM) cells when combined with proton radiation in vitro.

(S)-Seco-Duocarmycin SA is a DNA alkylating agent and antibiotic with potent antitumor activity that can be used to synthesize ADC compounds.

Seco-Duocarmycin SA is a highly potent DNA alkylator used as an ADC cytotoxin.

Anti-CCL2 (Carlumab)-MC-Vc-PAB-DMEA-PEG2-Duocarmycin SA is an antibody-drug conjugate (ADC) composed of the humanized anti-CCL2 (chemokine ligand 2) antibody Carlumab, linked with the MC-Vc-PAB-DMEA-PEG2 connector and the DNA alkylator Duocarmycin SA. This compound is utilized in cancer research.

Duocarmycin SA intermediate-2 is an intermediary compound in the synthesis of the antibiotic Duocarmycin SA. It can induce sequence-selective alkylation of double-stranded DNA (alkylation) and exhibits synergistic anticancer cytotoxicity when combined with proton radiation.